External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Urothelial Cell Carcinoma

Urothelial Cell Carcinoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Mar 21 / Roche and Genentech
A randomised, double-blind phase II study of autogene cevumeran + nivolumab (nivo) vs. nivo as adjuvant therapy for patients with high-risk muscle-invasive urothelial carcinoma (MIUC)
The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran (mRNA-based cancer vaccine) plus nivolumab compared with nivolumab in participants with high risk muscle-invasive urothelial cancer (MIUC).
Oncology Urothelial Cell Carcinoma EAU-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
Clinical outcomes in patients with high-risk, post-cystectomy MIBC with persistent circulating tumour DNA-negative status on serial testing: surveillance analysis from the IMvigor011 study
This poster reports data from the surveillance cohort of patients with high-risk MIBC from the global phase III IMvigor011 study. Clinical outcomes in patients who remained ctDNA negative following cystectomy based on serial ctDNA testing are included in the analysis.
Oncology Urothelial Cell Carcinoma EAU-2024

Sign up or login to unlock the full suite of MEDICALLY features
Feb 17 / Roche
Systematic literature review and testing of HER2 status in urothelial carcinoma (UC)
HER2 emerging as a possible therapeutic target in locally advanced and metastatic UC (LA/mUC). However, the prevalence of HER2 gene amplification and expression in LA/mUC is not yet well defined. Here, the Authors report findings from a systematic literature review of HER2 status in LA/mUC, as well as preliminary results of an ongoing evaluation of HER2 status, as assessed by protein and gene expression.
Oncology Urothelial Cell Carcinoma ASCO-GU-2023
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.